A new drug manufacturing facility has opened in the Altai Territory; its construction began in 2013.
The new facility will be engaged in producing synthetic drugs, that is, medicines derived from chemical synthesis. The production was launched by the Evalar company.
It is noteworthy that in addition to drug synthesis, the plant will also manufacture plant derived drugs.
The synthetic drug annual production capacity is expected to be 2 bln tablets and capsules.
Evalar was the sole financer of the new facility, providing a total of RUR 5 bln ($78 mio) for its construction.